相关实验视频

Updated: Apr 8, 2026

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Published on: September 14, 2010

宫状细胞癌中胺基因酶基因的表达特征通过各种检测方法得到证实

Cai Xia Liang¹, Ya Jun Pang², Man Yu Chen²

¹The First Clinical Medical School, Jinan University, Guangzhou 510632, Guangdong, China.

World journal of oncology

|January 24, 2025

概括

在宫平细胞癌 (CESC) 中,提米丁激酶1 (TK1) 被上调和TK2被下调. 不同的TK基因表达影响癌症进展和免疫透,表明潜在的治疗点.

科学领域:

分子瘤学和癌症生物标志物.
癌症中的DNA合成和修复机制.

背景情况:

蒂米丁激酶 (TKs) 对于DNA合成和修复至关重要,其改变的表达与各种癌症有关.
胺基酶1 (TK1) 和胺基酶2 (TK2) 在椎状细胞癌 (CESC) 中的作用仍然在很大程度上未被描述.
调查TK1和TK2对于理解CESC病原体和确定新的治疗策略至关重要.

研究的目的:

调查TK1和TK2在CESC中的差异表达.
在CESC中探索TK1和TK2的临床意义和分子机制.
评估TK1和TK2作为CESC的潜在生物标志物和治疗目标.

主要方法:

在918个CESC和360个对照组织中分析了TK1和TK2mRNA表达的全球高通量数据.
在62个CESC和对照组织中对TK1蛋白水平的免疫组织化学验证.
使用CRISPR淘汰数据评估TK1和TK2生长效应,并分析与免疫透和信号通路的关联.

主要成果:

在CESC组织中,TK1表达显著上调 (SMD: 2.44,AUC: 0.88) 和TK2显著下调 (SMD: -0.69,AUC: 0.75).
抑制TK1对CESC细胞系功能产生了负面影响,而TK2表达与恶性进展产生了负面相关性.
TK基因表达与免疫细胞透 (巨细胞,CD4+ T细胞,中性粒细胞) 和DNA复制和同源重组等途径有关.

结论:

TK1和TK2的差异表达是CESC的一个重要发现.
TK1和TK2代表了个性化CESC治疗的潜在诊断生物标志物和治疗点.
对TK相关途径的进一步研究可能会为CESC揭示新的治疗策略.

关键词:

子宫状细胞癌组织的组织.免疫系统的透.微阵列的微阵列通过RNA测序进行RNA测序.标准化平均差异差异标准化平均差异差异提米丁酶基因的基因

更多相关视频

Immunofluorescent Detection of Two Thymidine Analogues CldU and IdU in Primary Tissue

Immunofluorescent Detection of Two Thymidine Analogues CldU and IdU in Primary Tissue

Published on: December 7, 2010

Quantitative Fluorescence In Situ Hybridization FISH and Immunofluorescence IF of Specific Gene Products in KSHV-Infected Cells

Quantitative Fluorescence In Situ Hybridization FISH and Immunofluorescence IF of Specific Gene Products in KSHV-Infected Cells

Published on: August 27, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...